Hydreight Technologies Inc. Announces Closing of Oversubscribed $15 Million Bought Deal LIFE Offering

Article content

NOT FOR DISTRIBUTION TO UNITED STATES NEWS WIRE SERVICES OR 
FOR DISSEMINATION IN THE UNITED STATES

Article content

VANCOUVER, British Columbia, Jan. 27, 2026 (GLOBE NEWSWIRE) — Hydreight Technologies Inc. (TSXV: NURS, OTC: HYDTF, FSE: SO6) (“Hydreight” or the “Company“), a leader in U.S. nationwide digital healthcare solutions, is pleased to announce that, further to the news release of the Company dated January 15, 2026, it has closed its previously announced “bought deal” private placement with Canaccord Genuity Corp. (the “Lead Underwriter“) as lead underwriter and sole bookrunner, and Beacon Securities Limited (together with the Lead Underwriter, the “Underwriters“). The Company issued 3,705,000 units of the Company (each, a “Unit“) at a price of $4.05 per Unit for aggregate gross proceeds of $15,005,250 (the “Offering“). The Offering was conducted pursuant to an underwriting agreement dated January 27, 2026, between the Company and the Underwriters.

Article content

Article content

Article content

Shane Madden, the Chief Executive Officer of the Company, commented:

Article content

Article content

“This financing was oversubscribed within hours of announcement, reflecting strong conviction in Hydreight’s execution and the durability of our model. Q4 marked a clear inflection point for the business — expanding proven pharmacy product lines and launching high-demand products continued to drive real, scalable growth across all three verticals, and that momentum has carried decisively into 2026 with increasing visibility.

Article content

The addition of multiple new high quality institutional investors at this stage meaningfully and strategically bolsters our share register while providing further validation of our platform and is an important step as we scale. With this additional capital, we are positioned to further accelerate customer growth by expanding our technology and platform offerings, increasing production capacity, accelerating new product rollouts, and strengthening the infrastructure required to support growing demand across our nationwide network. We believe these investments position the Company for another year of outsized, exponential growth.”

Article content

Article content

The terms of the Offering consisted of the sale of up to 2,470,000 Units, subject to an option of the Underwriters to increase the number of offered Units by up to an additional 1,235,000 Units (the “Underwriters’ Option“). The Underwriters’ Option was exercised in full for a total of 1,235,000 additional Units. The Units were issued on a private placement basis (i) in reliance on the listed issuer financing exemption under Part 5A of National Instrument 45-106 – Prospectus Exemptions (“NI 45-106“) as modified by Coordinated Blanket Order 45-935 – Exemptions from Certain Conditions of the Listed Issuer Financing Exemption (the “Listed Issuer Financing Exemption“) in each of the Provinces and Territories of Canada, (ii) in the United States and to, or for the account or benefit of, U.S. persons pursuant to an exemption from the registration requirements of the United States Securities Act of 1933 (the “U.S. Securities Act”), as amended, and (iii) in such other jurisdictions other than Canada and the United States pursuant to relevant prospectus or registration exemptions in accordance with applicable laws, provided that no prospectus filing or comparable obligation, ongoing reporting or continuous disclosure requirement or requisite regulatory or governmental approval arose in such jurisdictions.